As part of this realignment, Pulse Biosciences will reduce its workforce in the sales and marketing departments while simultaneously ramping up recruitment in product development roles. The company aims to allocate more resources towards its catheter-based electrophysiology program, which has shown the potential to be both first-in-class and best-in-class. Bob Duggan, Co-Chairman of Pulse Biosciences, emphasized the importance of this initiative, stating, "The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this extraordinary opportunity."
The company is also expected to present additional data at the upcoming Heart Rhythm 2026 conference in Chicago, further showcasing the promising results of its nPulse Cardiac Catheter System. This strategic focus on the electrophysiology market is anticipated to enhance the company's growth trajectory and shareholder value in the long term.
